Innatera Selects Synopsys Simulation to Scale Brain-Inspired Processors for Edge Devices [Accessibility Statement] Skip Navigation--Pulsar Spiking Neural ProcessorSynopsys (PRNewsfoto/Synopsys)Innatera adopts Synopsys simulation technology to help design neuromorphic chips that enable low-power AI for wearables, smart home devices, and digital twin industrial sensorsKey Highlights- Synopsys Totemâ"¢ power integrity platform enables transistor-level analysis for reliable power delivery and performance optimi ...

Prices soared as investors flocked to safe-haven assets after the joint U.S.-Israeli strikes against Iran. ...

AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23, AbbVie (NYSE: ABBV) announced plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities. The new state-of-the-art facilities at the Illinois campus are to integrate advanced manufacturing technologies with artificial intelligence. Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? Artificial intelligence integration is part of AbbVie’s push to support and ...

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company has made significant progress in developing a broad portfolio of RAS(ON) inhibitors across multiple disease settings. Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs Daraxonrasib, a pioneering RAS(ON) multi-selective inhibitor, has already shown an unprecedented clin ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development. Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials During the year, the company submitted its first new drug application, setting the stage for potential FDA approval of a PROTAC degrader. The company has already presented topline results for ARV-806, a ...

Guardant Health Inc. (NASDAQ:GH) is one of the best cancer stocks to invest in now. On February 23, Guardant Health Inc. (NASDAQ:GH) completed the acquisition of the health technology company MetaSight Diagnostics. The $149 million acquisition comes as the company gears up for revenue growth in 2026. Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition With the acquisition, Guardant Health is to gain access to a range of next-generation liquid biopsies ...

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best cancer stocks to invest in now. On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by multiple value-creating regulatory catalysts. Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval ldutko/Shutterstock.com In January, the US Food and Drug Administration accepted the company’s PEAK New Drug Application for bezuclastinib in patient ...

Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules. Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development David Smart/Shutterstock.com The ultimate goal is to develop a targeted oncology platform for small molecules that can overcome resistance and ...

Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant progress on clinical and lifecycle milestones. Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key ...

Core Insights - Schrodinger Inc. is recognized as a promising investment in the cancer sector, showcasing strong revenue growth and a strategic shift towards a licensing model for more predictable revenue streams [1][3]. Financial Performance - Full-year revenue for 2025 increased by 23.3% to $255.9 million, with software revenue rising by 10.6% [3]. - Drug discovery revenue more than doubled to $56.4 million from $27.2 million in the previous year [3]. - Fourth-quarter revenue decreased by 1.2% year-over-year to $87.2 million, primarily due to a 13% decline in software revenue to $69.3 million [3]. - Drug discovery revenue in the fourth quarter surged to $18 million, up from $8.7 million in the same quarter of the prior year [3]. Profitability and Loss - The company's net loss for the full year decreased to $103.3 million from $187.1 million in 2024 [4]. - Schrodinger achieved profitability in the fourth quarter of FY25, reporting a net income of $32.5 million compared to a net loss of $40.2 million in the fourth quarter of 2024 [4]. Future Guidance - For 2026, the company projects software revenue between $218 million and $228 million, indicating a growth of 10-15% [5]. - Drug discovery revenue is anticipated to be in the range of $55 million to $65 million [5]. Company Overview - Schrodinger, Inc. operates as a healthcare technology company, providing a physics-based software platform for molecular simulation aimed at accelerating drug development and materials science [6].